Nasal spray live attenuated influenza vaccine: the first experience in Italy in children and adolescents during the 2020–21 season

Abstract Background In Italy only recently, for the 2020–21 season, has the flu vaccination been extended to all children. A quadrivalent live attenuated influenza vaccine (qLAIV) was administered to children aged 2–17 years for the first time. We registered the number and severity of adverse reacti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chiara Gasparini, Miriam Acunzo, Andrea Biuso, Stefania Roncaglia, Francesca Migliavacca, Catia R. Borriello, Caterina Bertolini, Michaela R. Allen, Annalisa Orenti, Patrizia Boracchi, Gian Vincenzo Zuccotti
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Influenza Widespread immunization Quadrivalent live attenuated influenza vaccine Children Adverse events Pediatrics RJ1-570
Acceso en línea:	https://doaj.org/article/b30a388a628745008d17e00a63005243
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b30a388a628745008d17e00a63005243
record_format	dspace
spelling	oai:doaj.org-article:b30a388a628745008d17e00a630052432021-11-14T12:43:39ZNasal spray live attenuated influenza vaccine: the first experience in Italy in children and adolescents during the 2020–21 season10.1186/s13052-021-01172-81824-7288https://doaj.org/article/b30a388a628745008d17e00a630052432021-11-01T00:00:00Zhttps://doi.org/10.1186/s13052-021-01172-8https://doaj.org/toc/1824-7288Abstract Background In Italy only recently, for the 2020–21 season, has the flu vaccination been extended to all children. A quadrivalent live attenuated influenza vaccine (qLAIV) was administered to children aged 2–17 years for the first time. We registered the number and severity of adverse reactions to (Fluenz Tetra™) and the factors influencing them, evaluated uniformity of access to care and assessed the degree of satisfaction with the vaccination of both parents and health care providers, in order to improve the 2021–22 vaccination program. Methods On vaccination day, a questionnaire was given out to collect information about the children and their parents. Between 1 and 3 months later, the parents were contacted to record any adverse reactions following (Fluenz Tetra™) and rate the degree of satisfaction. Results We received data of 3226 children from 2152 families. Adverse events were reported in 24.8% of children: 80.6% mild, 18.1% moderate and 1.3% significant. The most common were rhinitis (52.5%) and fever (24.4%). Statistical analysis performed with a multiple regression model, showed that children aged 2–5 years have an increased risk of adverse events compared to both 6–10 years old (aRR 1.7, 95% CI 1.5–1.9, p < 0. 001) and 11–17 years old (aRR 1.5, 95% CI 1–2.2, p = 0.051). Most families chose to vaccinate their children to protect them and because they were concerned about Covid19. The main channel through which parents became aware of a new flu vaccination was word-of-mouth (39.8%), which occurred mostly among parents of the same school group, followed by information from the child’s doctor (30.6%), the Internet (26.9%), personal research (15%), newspapers (4%), telecommunications (7.5%) and other (2.6%). Most parents (83.3%) were very satisfied and intend to vaccinate their children with qLAIV again (83.8%). The majority of operators (93%) considered the experience as excellent and are willing to repeat it (94.6%). Conclusion (Fluenz Tetra™) proved to be easy to administer and the degree of satisfaction was high among both health workers and parents. Considering its substantial safety profile especially in school-age children and adolescents, all these aspects make the nasal qLAIV optimal for widespread immunization. Schools offer the best setting to reach more families and physicians should be actively involved.Chiara GaspariniMiriam AcunzoAndrea BiusoStefania RoncagliaFrancesca MigliavaccaCatia R. BorrielloCaterina BertoliniMichaela R. AllenAnnalisa OrentiPatrizia BoracchiGian Vincenzo ZuccottiBMCarticleInfluenzaWidespread immunizationQuadrivalent live attenuated influenza vaccineChildrenAdverse eventsPediatricsRJ1-570ENItalian Journal of Pediatrics, Vol 47, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Influenza Widespread immunization Quadrivalent live attenuated influenza vaccine Children Adverse events Pediatrics RJ1-570
spellingShingle	Influenza Widespread immunization Quadrivalent live attenuated influenza vaccine Children Adverse events Pediatrics RJ1-570 Chiara Gasparini Miriam Acunzo Andrea Biuso Stefania Roncaglia Francesca Migliavacca Catia R. Borriello Caterina Bertolini Michaela R. Allen Annalisa Orenti Patrizia Boracchi Gian Vincenzo Zuccotti Nasal spray live attenuated influenza vaccine: the first experience in Italy in children and adolescents during the 2020–21 season
description	Abstract Background In Italy only recently, for the 2020–21 season, has the flu vaccination been extended to all children. A quadrivalent live attenuated influenza vaccine (qLAIV) was administered to children aged 2–17 years for the first time. We registered the number and severity of adverse reactions to (Fluenz Tetra™) and the factors influencing them, evaluated uniformity of access to care and assessed the degree of satisfaction with the vaccination of both parents and health care providers, in order to improve the 2021–22 vaccination program. Methods On vaccination day, a questionnaire was given out to collect information about the children and their parents. Between 1 and 3 months later, the parents were contacted to record any adverse reactions following (Fluenz Tetra™) and rate the degree of satisfaction. Results We received data of 3226 children from 2152 families. Adverse events were reported in 24.8% of children: 80.6% mild, 18.1% moderate and 1.3% significant. The most common were rhinitis (52.5%) and fever (24.4%). Statistical analysis performed with a multiple regression model, showed that children aged 2–5 years have an increased risk of adverse events compared to both 6–10 years old (aRR 1.7, 95% CI 1.5–1.9, p < 0. 001) and 11–17 years old (aRR 1.5, 95% CI 1–2.2, p = 0.051). Most families chose to vaccinate their children to protect them and because they were concerned about Covid19. The main channel through which parents became aware of a new flu vaccination was word-of-mouth (39.8%), which occurred mostly among parents of the same school group, followed by information from the child’s doctor (30.6%), the Internet (26.9%), personal research (15%), newspapers (4%), telecommunications (7.5%) and other (2.6%). Most parents (83.3%) were very satisfied and intend to vaccinate their children with qLAIV again (83.8%). The majority of operators (93%) considered the experience as excellent and are willing to repeat it (94.6%). Conclusion (Fluenz Tetra™) proved to be easy to administer and the degree of satisfaction was high among both health workers and parents. Considering its substantial safety profile especially in school-age children and adolescents, all these aspects make the nasal qLAIV optimal for widespread immunization. Schools offer the best setting to reach more families and physicians should be actively involved.
format	article
author	Chiara Gasparini Miriam Acunzo Andrea Biuso Stefania Roncaglia Francesca Migliavacca Catia R. Borriello Caterina Bertolini Michaela R. Allen Annalisa Orenti Patrizia Boracchi Gian Vincenzo Zuccotti
author_facet	Chiara Gasparini Miriam Acunzo Andrea Biuso Stefania Roncaglia Francesca Migliavacca Catia R. Borriello Caterina Bertolini Michaela R. Allen Annalisa Orenti Patrizia Boracchi Gian Vincenzo Zuccotti
author_sort	Chiara Gasparini
title	Nasal spray live attenuated influenza vaccine: the first experience in Italy in children and adolescents during the 2020–21 season
title_short	Nasal spray live attenuated influenza vaccine: the first experience in Italy in children and adolescents during the 2020–21 season
title_full	Nasal spray live attenuated influenza vaccine: the first experience in Italy in children and adolescents during the 2020–21 season
title_fullStr	Nasal spray live attenuated influenza vaccine: the first experience in Italy in children and adolescents during the 2020–21 season
title_full_unstemmed	Nasal spray live attenuated influenza vaccine: the first experience in Italy in children and adolescents during the 2020–21 season
title_sort	nasal spray live attenuated influenza vaccine: the first experience in italy in children and adolescents during the 2020–21 season
publisher	BMC
publishDate	2021
url	https://doaj.org/article/b30a388a628745008d17e00a63005243
work_keys_str_mv	AT chiaragasparini nasalsprayliveattenuatedinfluenzavaccinethefirstexperienceinitalyinchildrenandadolescentsduringthe202021season AT miriamacunzo nasalsprayliveattenuatedinfluenzavaccinethefirstexperienceinitalyinchildrenandadolescentsduringthe202021season AT andreabiuso nasalsprayliveattenuatedinfluenzavaccinethefirstexperienceinitalyinchildrenandadolescentsduringthe202021season AT stefaniaroncaglia nasalsprayliveattenuatedinfluenzavaccinethefirstexperienceinitalyinchildrenandadolescentsduringthe202021season AT francescamigliavacca nasalsprayliveattenuatedinfluenzavaccinethefirstexperienceinitalyinchildrenandadolescentsduringthe202021season AT catiarborriello nasalsprayliveattenuatedinfluenzavaccinethefirstexperienceinitalyinchildrenandadolescentsduringthe202021season AT caterinabertolini nasalsprayliveattenuatedinfluenzavaccinethefirstexperienceinitalyinchildrenandadolescentsduringthe202021season AT michaelarallen nasalsprayliveattenuatedinfluenzavaccinethefirstexperienceinitalyinchildrenandadolescentsduringthe202021season AT annalisaorenti nasalsprayliveattenuatedinfluenzavaccinethefirstexperienceinitalyinchildrenandadolescentsduringthe202021season AT patriziaboracchi nasalsprayliveattenuatedinfluenzavaccinethefirstexperienceinitalyinchildrenandadolescentsduringthe202021season AT gianvincenzozuccotti nasalsprayliveattenuatedinfluenzavaccinethefirstexperienceinitalyinchildrenandadolescentsduringthe202021season
_version_	1718429069070041088

Nasal spray live attenuated influenza vaccine: the first experience in Italy in children and adolescents during the 2020–21 season

Ejemplares similares